

5 key facts about **cholangiocarcinoma**



Although rare, the incidence of **cholangiocarcinoma**, in particular **intrahepatic cholangiocarcinoma**, is generally **increasing worldwide**¹



~70% of patients with **cholangiocarcinoma** are diagnosed with **advanced disease**, which compromises **therapeutic options** and leads to a **poor prognosis**²

A **multidisciplinary team approach** enables a more **comprehensive understanding of disease biology** and **collaboration options** for patients with **cholangiocarcinoma**³



Biopsy technique should account for planned **molecular profiling** as well as **diagnostic needs**⁴

~50% of patients with **cholangiocarcinoma** have at least **one potentially actionable genomic alteration**, supporting the rationale for **molecular profiling at diagnosis**⁵



If you would like to request further medical information, please visit: www.incyteglobalmedicalinformation.com

REFERENCES:

1. Bañales JM, et al. *Nat Rev Gastroenterol Hepatol*. 2016;13:261–80;
2. Bañales JM, et al. *Nat Rev Gastroenterol Hepatol*. 2020;17:557–88;

3. Patel T. *Nat Rev Gastroenterol Hepatol*. 2011;8:189–200;
4. Cree IA, et al. *J Clin Pathol*. 2014;67:923–31;

5. Lowery MA, et al. *Clin Cancer Res*. 2018;24:4154–61.